Search Results
Jun 01, 2026, 01:30 ET MSI Accelerates Enterprise AI Strategy with Cloud-to-Edge Ecosystem at COMPUTEX 2026
computing, and ground control systems. Built for harsh environments, this comprehensive platform combines drone ground control stations, rugged tablets, T-Box connectivity modules, and centralized multi-drone management platforms. It is engineered for critical use cases including automated field inspection,
More news about: MSI
May 31, 2026, 22:37 ET ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
platform incorporates customized "armoring" elements designed to modulate T cell metabolic pathways and signal transduction based on the specific tumor microenvironment (TME). This engineering strategy enriches young, stem-like memory T cell subsets (Tscm), significantly enhancing the in vivo persistence
More news about: Oricell Therapeutics Holdings Limited
May 31, 2026, 20:15 ET Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2), as sequential therapy after first-line
More news about: CARsgen Therapeutics
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
profile demonstrated saturated receptor occupancy and robust T-cell activation/proliferation confirming PD-1/CTLA-4 blockade and deep and sustained VEGFA neutralization.Receptor occupancy (RO) of PD-1/CTLA-4 on peripheral T cells reached saturation throughout the dosing interval at
More news about: CStone Pharmaceuticals
May 31, 2026, 20:00 ET ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. As of the data cut-off on January 31, 2026, the optimized dose of MVR-T3011 achieved a 100% complete response rate (CRR)
More news about: ImmVira Group
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
enrichment, M2‑like tumor‑associated macrophage polarization, and effector T‑cell exhaustion. Re‑activation and sustained stimulation of anti‑tumor immunity are required. Continuous high‑intensity IL‑2 signaling reinvigorates exhausted T cells and reverses TME‑mediated immune suppression.IBI363
More news about: Innovent Biologics
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F. (2023). Vorasidenib in idh1- or
More news about: Servier Pharmaceuticals
May 31, 2026, 16:32 ET Creality Rayakan 12 Tahun Inovasi dengan KliTek™ dan Ekspansi Ekosistem Berbasis AI
rekomendasi parameter otomatis, serta deteksi risiko pencetakan yang menyederhanakan alur kerja, mulai dari proses kreasi hingga produksi.Falcon T1 — platform laser multifungsi untuk pengukiran, pemotongan, dan fabrikasi presisi.Pika & Sermoon P1 Scanner — solusi pemindaian
More news about: Creality
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard
More news about: Akeso, Inc.
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
selectivity over wild-type EGFR. Preclinical and clinical data support its potent activities against single, double and triple EGFR mutations (L858R/19del, T790M, C797X).Golidocitinib: A JAK1 Inhibitor Combined with Anti-PD-1 Demonstrates Durable Clinical BenefitAmong 47 enrolled treatment-naïve
More news about: Dizal Pharmaceutical
May 30, 2026, 16:57 ET Creality đánh dấu cột mốc 12 năm với KliTek™ và mở rộng hệ sinh thái được hỗ trợ bởi AI
ưu hóa cắt lớp thông minh, đề xuất thông số tự động và phát hiện rủi ro in nhằm đơn giản hóa quy trình từ khâu sáng tạo đến sản xuất.Falcon T1 — Nền tảng laser đa chức năng tiên tiến được thiết kế để hỗ trợ các hoạt động sản xuất sáng tạo trong các quy trình khắc, cắt và gia công chính xác.Máy
More news about: Creality
May 30, 2026, 16:52 ET 크리얼리티, KliTek™와 AI 기반 생태계 확장으로 12주년 맞아
Cloud AI Ecosystem Upgrade — AI 지원 모델링, 지능형 슬라이싱 최적화, 자동 파라미터 추천, 출력 위험 감지 기능을 도입하는 주요 플랫폼 업그레이드로, 창작에서 생산까지의 워크플로를 간소화하도록 설계됐다.Falcon T1 — 인그레이빙, 커팅, 정밀 제작 워크플로 전반에서 창의적인 생산을 지원하도록 설계된 고급 다기능 레이저 플랫폼이다.Pika & Sermoon P1 Scanner — 휴대형 설계, 지능형 이미징, 고정밀 디지털 캡처 기능을 결합한
More news about: Creality
May 30, 2026, 15:55 ET Tulsa's Route 66 Capital Cruise Sets GUINNESS WORLD RECORDS™ Mark
https://brandfolder.com/s/s739mggsmvnjk5jjkkqb55t4 This link is live and will update as more assets are added
More news about: Visit Tulsa
May 30, 2026, 15:19 ET 엔진AI, 선전 지능형 제조 기지 가동하며 1차 T800 휴머노이드 로봇 생산 완료 및 대규모 납품 개시
휴머노이드 로봇 혁신 기업 엔진AI 로보틱스(EngineAI Robotics)가 엔진AI 지능형 제조(선전 훙화링) 기지(EngineAI Intelligent Manufacturing (Honghualing, Shenzhen) Base)의 공식 출범과 함께 자사의 플래그십 T800 풀사이즈 휴머노이드 로봇 1차 물량이 생산라인에서 출고됐다고 발표했다. 이번 이정표는 회사가 1만 대 규모의 납품 역량을 갖춘 새로운 단계에 본격적으로 진입했음을 의미한다.
More news about: EngineAI
May 30, 2026, 15:15 ET EngineAI Resmikan Pabrik Cerdas di Shenzhen, Robot Humanoid T800 Mulai Dikirim secara Massal
meresmikan Pabrik Cerdas EngineAI (Honghualing, Shenzhen), serta mulai memproduksi robot humanoid berukuran besar sebagai produk unggulannya, T800. Perkembangan ini menandai langkah strategis EngineAI memasuki fase baru dengan kapasitas pengiriman 10.000 unit.
More news about: EngineAI
May 30, 2026, 11:35 ET /C O R R E C T I O N -- Hyundai Motor America/
More news about: Hyundai Motor America
May 30, 2026, 08:05 ET ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
Brachman DG. The role of GammaTile in the treatment of brain tumors: a technical and clinical overview. J Neurooncol. 2024;166:203-212.Kutuk T, Kotecha R, Herrera R, et al. Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis
More news about: GT Medical Technologies
May 30, 2026, 06:52 ET Menarini Group、ASCO2026でER+/HER2-転移性乳がん対象エラセストラント・カピバセルチブ併用ELEVATE試験の新データを発表
NCT06492616）は、再発リスクの高いリンパ節転移陽性、ER+、HER2-の早期乳がんの女性および男性を対象に、エラセストラントの有効性を標準内分泌療法と比較評価する第3相試験です。エラセストラントはまた、転移性乳おがんよび早期乳がんを対象に、医師主導の臨床試験や他社との共同試験で評価されています。副作用の疑いがある場合は、Stemline Therapeutics, Inc.（
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 06:29 ET EngineAI ra mắt cơ sở sản xuất thông minh tại Thâm Quyến, lô robot hình người T800 đầu tiên xuất xưởng, bắt đầu giao hàng quy mô lớn
thức đưa vào hoạt động Cơ sở Sản xuất Thông minh EngineAI (Honghualing, Thâm Quyến), đồng thời xuất xưởng lô robot hình người kích thước đầy đủ T800 chủ lực đầu tiên. Cột mốc này đánh dấu bước tiến quyết định của công ty sang giai đoạn mới với năng lực giao hàng có khả năng mở rộng lên quy mô 10.000
More news about: EngineAI
May 30, 2026, 06:28 ET EngineAI、深センインテリジェント製造基地を立ち上げ、量産型ヒューマノイドロボット「T800」の初出荷分がラインオフし、本格的な納品を開始
深セン、中国、2026年5月29日 /PRNewswire/ -- ヒューマノイドロボットのイノベーターであるEngineAI Roboticsは本日、フラッグシップであるフルサイズヒューマノイドロボット「T800」の初出荷分のラインオフと同時に、「EngineAIインテリジェント製造（深セン市紅花嶺）基地」の正式な立ち上げを発表しました。このマイルストーンは、同社が1万台規模のスケーラブルな納品能力を備えた新たな段階へと決定的に突入したことを意味します。
More news about: EngineAI
May 30, 2026, 06:27 ET 眾擎機器人深圳智能製造基地啟用 首批T800人形機器人量產下線交付
View original content to download multimedia:https://www.prnewswire.com/apac/zh/news-releases/-t800-302786244.htmlSOURCE EngineAI
More news about: EngineAI
May 29, 2026, 17:48 ET Researchers From NYU Langone Health's Perlmutter Cancer Center Present Latest Findings at 2026 ASCO Annual Meeting
Medicine, will present a study on a new type of CAR T-cell therapy for patients with advanced solid tumors in a first-in-human phase 1/2 clinical trial in progress. The study, called EVEREST-2, is testing A2B543, an investigational "logic-gated" CAR T-cell therapy designed to better distinguish cancer
More news about: NYU Langone Health System
May 29, 2026, 17:07 ET Harley-Davidson Apparel, Riding Gear, and FREE WHEEL FRIDAYS Drive Rider Engagement at Tilley Harley-Davidson of Statesville
the 2026 Don Tilley Dice RunRiders can now register for the upcoming 2026 Don Tilley Dice Run and receive an exclusive commemorative event t-shirt while supplies last. The annual ride celebrates and honors the life and legacy of legendary Harley-Davidson tuner and dealership founder Don Tilley
More news about: Tilley Harley-Davidson